In this open-label , phase 3 trial , we randomly assigned 704 patients with metastatic melanoma with a BRAF V600 mutation to receive either a combination of dabrafenib ( 150 mg twice daily ) and trametinib ( 2 mg once daily ) or vemurafenib ( 960 mg twice daily ) orally as first-line therapy .